This page shows the latest Immutep news and features for those working in and with pharma, biotech and healthcare.
Analyst Dr Chris Redhead at Goetzpartners said the outcomes was a “substantial setback” for Immutep, but doesn’t mean that efti is dead. ... Immutep will need to keep its foot on the gas if it hopes to keep pace with some larger, deep-pocketed
Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... Immutep also has a phase 2b trial of efti ongoing
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
No results were found
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys...